This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Late Stage Chronic Kidney Disease Therapeutics Market

Market Insights on Late Stage Chronic Kidney Disease Therapeutics covering sales outlook, demand forecast & up-to-date key trends

Late Stage Chronic Kidney Disease Therapeutics Market By Product Type, Indication, End Users & Region - Forecast 2022-2032

Late Stage Chronic Kidney Disease Therapeutics Market Snapshot (2022-2032)

[250 Pages Report] The global demand for late stage chronic kidney disease therapeutics was valued at around US$ 4.7 Billion in 2019. However, with rising prevalence of chronic kidney disease across the globe, the overall late stage kidney disease therapeutics market is anticipated to surpass US$ 11.1 Billion in 2027 and forecast to grow at a prolific CAGR of around 11.6% throughout the forecast period (2022 –2032)

Report Attribute

Details

Late Stage Chronic Kidney Disease Therapeutics Market Projected Growth Rate (2022-2032)

11.6% CAGR

Chronic kidney disease (CKD) has been recognized as a leading public health problem worldwide due to its high morbidity and mortality rates. This fatal disease is usually caused by diabetes mellitus, hypertension, obesity, and aging.

Late stage chronic disease is an advanced stage of chronic renal disease where kidneys no longer function or work. This reduces the chances of survival and therefore requires proper treatment approaches including kidney transplant, dialysis and therapeutics. Among these, kidney transplant and dialysis are the only two effective treatments for CKD. However, dialysis is often costly and transplantation is limited by organ shortage. This has brought late stage chronic kidney disease therapeutics market into the spotlight.

Majority of the people with lower socioeconomic status and limited access to treatments are highly dependent on late stage chronic kidney disease therapeutics. These therapeutics can also be used in combination with dialysis.

Late stage chronic kidney disease therapeutics are drugs used for the treatment of late-stage chronic kidney disease induced hyperkalemia, hyperphosphatemia, hyperparathyroidism. Consumption of late stage chronic kidney disease therapeutics help to relieve the symptoms of CKD, delay late stage chronic kidney disease development, and thus enable patients to live longer lives without going through dialysis or transplantation.

Customize this Report

Let us know your requirement to get
100% FREE customization

Which Factors are Expected to Augment Growth of Late Stage Chronic Kidney Disease Therapeutics Market

Rising prevalence of chronic kidney disease (CKD) worldwide, rising awareness among people regarding the benefits of late stage chronic kidney disease therapeutics, introduction of favorable reimbursement policies for CKD treatment, higher diagnostic rates, and development of new effective therapeutics are some of the major factors expected to boost the growth of late stage chronic kidney disease therapeutics market during the forecast period.

Increasing incidence of chronic kidney disease is perhaps the major factor behind the robust expansion of late stage chronic disease therapeutics market. According to a report published in the Lancet, global prevalence of chronic kidney diseases reached around 700 million in 2017 and the numbers are expected to further surge during the upcoming years.

Similarly, the introduction of new advanced late stage kidney disease therapeutics along with poor access to renal replacement therapy and dialysis in developing countries is expected to favor market growth during the assessment period.

What are the Challenges Faced by the Late Stage Chronic Kidney Disease Therapeutics Industry

Despite its optimistic stance, the late stage chronic kidney disease therapeutics market is facing various obstacles that are restraining its growth to some extent. Some of these growth restraining factors are the delay in the diagnosis of CKD and increase in the number of kidney transplants.

Similarly, various side effects associated with late stage chronic kidney disease therapeutics is also limiting market growth.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Why is North America Considered a Prominent Market for Late Stage Chronic Kidney Disease Therapeutics

According to Future Market Insights, North America accounted for the largest share of the global late stage chronic kidney disease therapeutics market in 2021 and is projected to grow at the fastest CAGR over the forecast period. Growth in the market is attributable to the rising incidence of chronic kidney disease, availability of favorable reimbursement policies, and heavy presence of leading market players.

Demand for late stage chronic kidney disease therapeutics is particularly high across the United States due to surge in chronic kidney disease cases and easy availability of advanced therapeutics. According to the Centers for Disease Control and Prevention (CDC), around 37 million people in the United States are estimated to have chronic kidney disease.

How Will Market Fare Across Asian Pacific

The Asia Pacific late stage chronic kidney disease therapeutics market is anticipated to grow at a considerable pace during the forecast period between 2022 and 2032, owing to the rising health awareness, growing prevalence of chronic kidney disease, and increasing government initiatives and investments to reduce the burden of chronic kidney disease.

According to the National Kidney Foundation, number of cases of kidney failure is expected to surge rapidly in developing countries, such as China and India, where the number of elderly people is increasing. This will generate lucrative growth prospects within the Asia Pacific late stage chronic kidney disease therapeutics market during the forecast period.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Market Competition

Some of the key participants present in the global late stage chronic kidney disease therapeutics market includes Amgen, Deltanoid, AbbVie, Sanofi, Ardelyx, AstraZeneca, Kyowa Hakko Kirin, Genzyme, Keryx, Spectrum, Mitsubishi Tanabe, OPKO Health, Relypsa, Shield Therapeutics, Shire,  Vifor and ZS Pharma among others.

These leading players are continuously investing in research and development to introduce more effective therapeutics. Besides this, they are partnering and collaborating with dialysis centers to increase their sales and gain a competitive edge in the market.

Report Scope

Report Attribute

Details

Growth Rate

CAGR of 11.6% from 2022 to 2032

Base Year for Estimation

2021

Historical Data

2015-2020

Forecast Period

2022-2032

Quantitative Units

Revenue in USD Million and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Product Type
  • Indication
  • End Users
  • Region

Regions Covered

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Argentina
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASEAN
  • GCC
  • South Africa

Key Companies Profiled

  • Amgen
  • Deltanoid
  • AbbVie
  • Sanofi
  • Ardelyx
  • AstraZeneca
    Kyowa Hakko Kirin
  • Genzyme, Keryx
  • Spectrum
  • Mitsubishi Tanabe
  • OPKO Health
  • Relypsa
  • Shield Therapeutics
  • Shire
  • Vifor
  • ZS Pharma

Customization

Available Upon Request

Key Segments Profiled in the Late Stage Chronic Kidney Disease Therapeutics Industry Survey

By Product Type:

  • Calcimimetics
  • Sensipar (cinacalcet hydrochloride)
  • Vitamin D Sterols
  • Nutritional/Native Vitam:in D
  • Vitamin D Receptor Agonists
  • Phosphate Binders
  • Calcium-Based Phosphate Binders
  • Aluminum-Containing Phosphate Binders
  • Magnesium-Containing Phosphate Binders
  • Renvela/Renagel
  • Fosrenol (lanthanum carbonate)
  • Velphoro (sucroferric oxyhydroxide)
  • Auryxia (ferric citrate)
  • Potassium Binders
  • Resins
  • Veltassa (patiromer sorbitex calcium)

By Indication:

  • Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
  • Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
  • Late Stage Chronic Kidney Disease Induced Hyperkalemia

By End Users:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Mail Order Pharmacy

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East & Africa

Frequently Asked Questions

FMI projects the global late stage chronic kidney disease therapeutics market to expand at a stupendous CAGR of around 11.6% through 2032.

North America is forecast to remain the most lucrative market for late stage chronic kidney disease therapeutics during the assessment period.

Amgen, Deltanoid, AbbVie, Sanofi, Ardelyx, AstraZeneca, Kyowa Hakko Kirin, Genzyme, Keryx, and Spectrum are some prominent late stage chronic kidney disease therapeutics manufacturers

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. Value Chain Analysis

        3.5.1. Profit Margin Analysis

        3.5.2. Service Providers

    3.6. PESTLE and Porter’s Analysis

    3.7. Regulatory Landscape

        3.7.1. By Key Regions

        3.7.2. By Key Countries

    3.8. Regional Parent Market Outlook

4. Global Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2022-2032

        5.3.1. Calcimimetics

        5.3.2. Vitamin D Sterols

        5.3.3. Phosphate Binding Therapies

        5.3.4. Potassium Binding Therapies

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2022-2032

Deep-dive segmentation will be available in the sample on request

6. Global Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Indication

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Indication, 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Indication, 2022-2032

        6.3.1. Late-stage Chronic Kidney Disease - Induced Hyperparathyroidism

        6.3.2. Late-stage Chronic Kidney Disease - Induced Hyperphosphatemia

        6.3.3. Late-stage Chronic Kidney Disease - Induced Hyperkalemia

    6.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Indication, 2022-2032

Deep-dive segmentation will be available in the sample on request

7. Global Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Mail Order Pharmacies

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032

Deep-dive segmentation will be available in the sample on request

8. Global Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

    8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. East Asia

        8.3.5. South Asia & Pacific

        8.3.6. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. U.S.

            9.2.1.2. Canada

        9.2.2. By Drug Class

        9.2.3. By Indication

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Indication

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Mexico

            10.2.1.2. Brazil

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Class

        10.2.3. By Indication

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Indication

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. Italy

            11.2.1.3. France

            11.2.1.4. U.K.

            11.2.1.5. Spain

            11.2.1.6. BENELUX

            11.2.1.7. Russia

            11.2.1.8. Rest of Europe

        11.2.2. By Drug Class

        11.2.3. By Indication

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Indication

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. East Asia Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Drug Class

        12.2.3. By Indication

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Indication

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. ASEAN

            13.2.1.3. Australia and New Zealand

            13.2.1.4. Rest of South Asia & Pacific

        13.2.2. By Drug Class

        13.2.3. By Indication

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Indication

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. MEA Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. Turkey

            14.2.1.3. South Africa

            14.2.1.4. Rest of MEA

        14.2.2. By Drug Class

        14.2.3. By Indication

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Indication

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. Key Countries Late Stage Chronic Kidney Disease Therapeutics Market Analysis

    15.1. U.S.

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2021

            15.1.2.1. By Drug Class

            15.1.2.2. By Indication

            15.1.2.3. By Distribution Channel

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2021

            15.2.2.1. By Drug Class

            15.2.2.2. By Indication

            15.2.2.3. By Distribution Channel

    15.3. Mexico

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2021

            15.3.2.1. By Drug Class

            15.3.2.2. By Indication

            15.3.2.3. By Distribution Channel

    15.4. Brazil

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2021

            15.4.2.1. By Drug Class

            15.4.2.2. By Indication

            15.4.2.3. By Distribution Channel

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2021

            15.5.2.1. By Drug Class

            15.5.2.2. By Indication

            15.5.2.3. By Distribution Channel

    15.6. Italy

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2021

            15.6.2.1. By Drug Class

            15.6.2.2. By Indication

            15.6.2.3. By Distribution Channel

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2021

            15.7.2.1. By Drug Class

            15.7.2.2. By Indication

            15.7.2.3. By Distribution Channel

    15.8. U.K.

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2021

            15.8.2.1. By Drug Class

            15.8.2.2. By Indication

            15.8.2.3. By Distribution Channel

    15.9. Spain

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2021

            15.9.2.1. By Drug Class

            15.9.2.2. By Indication

            15.9.2.3. By Distribution Channel

    15.10. BENELUX

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2021

            15.10.2.1. By Drug Class

            15.10.2.2. By Indication

            15.10.2.3. By Distribution Channel

    15.11. Russia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2021

            15.11.2.1. By Drug Class

            15.11.2.2. By Indication

            15.11.2.3. By Distribution Channel

    15.12. China

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2021

            15.12.2.1. By Drug Class

            15.12.2.2. By Indication

            15.12.2.3. By Distribution Channel

    15.13. Japan

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2021

            15.13.2.1. By Drug Class

            15.13.2.2. By Indication

            15.13.2.3. By Distribution Channel

    15.14. South Korea

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2021

            15.14.2.1. By Drug Class

            15.14.2.2. By Indication

            15.14.2.3. By Distribution Channel

    15.15. India

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2021

            15.15.2.1. By Drug Class

            15.15.2.2. By Indication

            15.15.2.3. By Distribution Channel

    15.16. ASEAN

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2021

            15.16.2.1. By Drug Class

            15.16.2.2. By Indication

            15.16.2.3. By Distribution Channel

    15.17. Australia and New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2021

            15.17.2.1. By Drug Class

            15.17.2.2. By Indication

            15.17.2.3. By Distribution Channel

    15.18. GCC Countries

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2021

            15.18.2.1. By Drug Class

            15.18.2.2. By Indication

            15.18.2.3. By Distribution Channel

    15.19. Turkey

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2021

            15.19.2.1. By Drug Class

            15.19.2.2. By Indication

            15.19.2.3. By Distribution Channel

    15.20. South Africa

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2021

            15.20.2.1. By Drug Class

            15.20.2.2. By Indication

            15.20.2.3. By Distribution Channel

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Drug Class

        16.3.3. By Indication

        16.3.4. By Distribution Channel

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Amgen Inc.

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

                17.1.1.5.2. Product Strategy

                17.1.1.5.3. Channel Strategy

        17.1.2. OPKO Pharmaceuticals Medtronic Plc.

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

                17.1.2.5.2. Product Strategy

                17.1.2.5.3. Channel Strategy

        17.1.3. Abbott Laboratories 

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

                17.1.3.5.2. Product Strategy

                17.1.3.5.3. Channel Strategy

        17.1.4. Sanofi-Aventis U.S.

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

                17.1.4.5.2. Product Strategy

                17.1.4.5.3. Channel Strategy

        17.1.5. Takeda Pharmaceutical

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

                17.1.5.5.2. Product Strategy

                17.1.5.5.3. Channel Strategy

        17.1.6. Vifor Pharma

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

                17.1.6.5.2. Product Strategy

                17.1.6.5.3. Channel Strategy

        17.1.7. Akebia Therapeutics

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

                17.1.7.5.2. Product Strategy

                17.1.7.5.3. Channel Strategy

        17.1.8. AstraZeneca

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

                17.1.8.5.2. Product Strategy

                17.1.8.5.3. Channel Strategy

        17.1.9. Kyowa Hakko Kirin

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

                17.1.9.5.2. Product Strategy

                17.1.9.5.3. Channel Strategy

        17.1.10. Galenica Group

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

                17.1.10.5.2. Product Strategy

                17.1.10.5.3. Channel Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Region, 2017-2032

Table 2: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 3: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 4: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 5: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 6: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 7: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 8: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 9: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 10: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 11: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 12: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 13: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 14: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 15: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 16: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 17: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 18: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 19: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 20: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 21: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 22: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 23: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 24: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 25: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 26: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 27: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 28: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 2: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Indication, 2022-2032

Figure 3: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 4: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Region, 2022-2032

Figure 5: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Region, 2017-2032

Figure 6: Global Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 7: Global Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 8: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 9: Global Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 10: Global Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 11: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 12: Global Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 13: Global Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 14: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 15: Global Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 16: Global Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 17: Global Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Drug Class, 2022-2032

Figure 18: Global Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Indication, 2022-2032

Figure 19: Global Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 20: Global Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Region, 2022-2032

Figure 21: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 22: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Indication, 2022-2032

Figure 23: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 24: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 25: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 26: North America Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 27: North America Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 28: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 29: North America Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 30: North America Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 31: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 32: North America Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 33: North America Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 34: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 35: North America Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 36: North America Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 37: North America Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Drug Class, 2022-2032

Figure 38: North America Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Indication, 2022-2032

Figure 39: North America Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 40: North America Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Country, 2022-2032

Figure 41: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 42: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Indication, 2022-2032

Figure 43: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 44: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 45: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 46: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 47: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 48: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 49: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 50: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 51: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 52: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 53: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 54: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 55: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 56: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 57: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Drug Class, 2022-2032

Figure 58: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Indication, 2022-2032

Figure 59: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 60: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Country, 2022-2032

Figure 61: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 62: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Indication, 2022-2032

Figure 63: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 64: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 65: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 66: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 67: Europe Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 68: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 69: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 70: Europe Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 71: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 72: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 73: Europe Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 74: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 75: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 76: Europe Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 77: Europe Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Drug Class, 2022-2032

Figure 78: Europe Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Indication, 2022-2032

Figure 79: Europe Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 80: Europe Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Country, 2022-2032

Figure 81: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 82: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Indication, 2022-2032

Figure 83: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 84: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 85: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 86: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 87: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 88: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 89: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 90: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 91: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 92: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 93: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 94: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 95: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 96: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 97: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Drug Class, 2022-2032

Figure 98: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Indication, 2022-2032

Figure 99: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 100: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Country, 2022-2032

Figure 101: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 102: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Indication, 2022-2032

Figure 103: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 104: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 105: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 106: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 107: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 108: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 109: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 110: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 111: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 112: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 113: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 114: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 115: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 116: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 117: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Drug Class, 2022-2032

Figure 118: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Indication, 2022-2032

Figure 119: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 120: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Country, 2022-2032

Figure 121: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 122: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Indication, 2022-2032

Figure 123: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 124: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 125: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 126: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 127: MEA Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 128: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 129: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 130: MEA Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 131: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 132: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 133: MEA Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 134: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 135: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 136: MEA Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 137: MEA Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Drug Class, 2022-2032

Figure 138: MEA Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Indication, 2022-2032

Figure 139: MEA Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 140: MEA Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Hepatitis - B Therapeutics Market

Published : February 2016

Healthcare

Peptide Therapeutics Market

Published : February 2022

Healthcare

Lung Cancer Therapeutics Market

Published : February 2022

Healthcare

Leukemia Therapeutics Treatment Market

Published : February 2022

Google translate

Late Stage Chronic Kidney Disease Therapeutics Market